



Together We Discover

Corporate Presentation
April 2023



Forward Looking Statements

This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

Certain statements contained in this presentation, other than present and historical facts and conditions independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include those regarding preliminary financial results for the full year 2022; expectations of future profitability; plans for geographic expansion; the anticipated launch of argenx’s subcutaneous (“SC”) product in the U.S.; the initiation, timing, progress and results of our anticipated clinical development, data readouts and regulatory milestones and plans; strategic priorities, including the timing and outcome of regulatory filings and regulatory approvals, and anticipated expansion in generalized myasthenia gravis (gMG) and IgG-mediated autoimmune diseases; the potential of argenx’s innovative clinical programs; and the nomination of new development candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (“SEC”) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this presentation. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners.

We are on a **bold mission**

Transforming the lives of patients with
severe autoimmune disease through
immunology innovation

Redefining Autoimmune Diseases With Precision Medicine Approach

Autoimmunity
is Prime for
REVOLUTION

A pipeline of **precision tools**

Redefine our pipeline of autoimmune diseases as **IgG-mediated or complement-driven**

Offer **new targeted treatment** modality in diseases where **innovation** is most needed

Redefining What 'Well-Controlled' Means for the Patient

We want to transform gMG treatment for patients

Achieve minimal symptom expression

Reduce reliance on broad immunosuppressants

Minimize treatment burden

Regain control of their lives, including professionally and socially



...and gMG
is just the
beginning

Pioneer with
Our Science

Lead with
Compassion for
our Patients

argenx 2025: A Leading, Sustainable
Immunology Company

Drive Impact
Through
Innovation

Build the
Company We
Want to Work
For


2022: Transformed into an Integrated Immunology Company

VYVGART launched in U.S., Japan & Germany

SUBMISSIONS IN **10+ COUNTRIES**

Built scalable global supply chain

LARGE SCALE CAPACITY TO **HANDLE DEMAND**



Rapid HCP adoption

90% of KEY TARGETS REACHED in 2022

Enabled appropriate access through value-based agreements


90% US POLICIES FAVORABLE

More than 3,000 patients on VYVGART®


2022: Strengthened Efgartigimod Data Story

SC Noninferiority to IV

IgG reduction (%) in all ADAPT-SC and ADAPT participants



Clear Clinical Benefit in ITP



Broadened Safety Database

>1,300 clinical study subjects

Cyclic and chronic dosing


Cumulative exposure of >1,000 patient years

TEAEs consistent across >4 indications; typically mild to moderate


Solidifying FcRn Leadership with Deep Repertoire of Preclinical and Translational Data



2023: Key Drivers of our Path to Profitability



Reach More Patients with VYVGART Globally



IgG Autoantibodies Serve as Unifying Biology Rationale for POC Indications

clinical

Pioneer FcRn class
of medicines

Contactin1

DSG-1

Ro/SSA

Mi-2

La/SSB

THSd7A

MPO-ANCA

PLA2R

ANA

NF155

DSG-3

GPIIb/IIIa

HMGCR

BP230

DSA

NELL1

AChR

PR3-ANCA

GPCR

MuSK

BP180

LRP4


TSHR

JO-1

SRP

Immune
complexes

Pipeline-in-a-Product Indicates Significant Market Opportunity




Steady Cadence of Data Readouts Over Next Several Years



Late Stage

Proof-of-Concept



*GO/NO GO Decisions.


Patient numbers are U.S. prevalence from argenx market research

ARGX-117: Targets C2 at Junction of Classical and Lectin Pathways

clinical
Broaden
immunology
pipeline

ARGX-117: Sweeping Antibody

Three Indications Selected Based on Biology Rationale





Indication selection starts with autoimmune diseases driven by classical and/or lectin pathway

Phase 2 proof-of-concept trial underway in multifocal motor neuropathy (MMN) with interim data expected in mid-2023

Phase 2 trials to start in delayed graft function and dermatomyositis



ARGX-117: Strong Translational Biology Rationale for C2 Blockade in MMN



Significant reduction of injury to paranodal proteins at the Nodes of Ranvier improves respiratory function *in vivo*

ARGX-119: MuSK Agonist with Broad Potential in Neuromuscular Disease

clinical
Broaden
immunology
pipeline



First-in-Patient

Congenital
Myasthenic
Syndrome (CMS)

First-in-patient trial in CMS to serve as proof of biology

Translational work ongoing in amyotrophic lateral sclerosis (ALS)

Positioned for Long-term Franchise Growth

Neurology

gMG, CIDP,
Myositis, TED, MMN, CMS,
Musk MG, ALS

Hematology and
Rheumatology

ITP, Sjogren's, POTS, Anca
Vasculitis

Dermatology


Pemphigus, Bullous
Pemphigoid,
Dermatomyositis

Nephrology

Membranous
Nephropathy, Lupus
Nephritis, AMR, DGF

Innovation Ecosystem

discovery
Build out
innovation
ecosystem



Positioned for a Catalyst-Rich 2023

Planned Commercial Milestones

VYVGART gMG Approval in China	YE 2023
VYVGART gMG Approval in Canada	3Q 2023
VYVGART gMG Launch in France, UK, Italy	YE 2023
SC efgartigimod gMG PDUFA Date	June 20, 2023
SC efgartigimod gMG Approval in EU	4Q 2023
SC efgartigimod gMG Submission in Japan	1Q 2023
VYVGART ITP Submission in Japan	Mid-2023

Planned Clinical Milestones

Efgartigimod

- ADHERE data in CIDP 2Q 2023
- ADDRESS data in Pemphigus 2H 2023
- ADVANCE (SC) data in ITP 2H 2023
- POC data in Post-COVID POTS 4Q 2023
- Initiate registrational trial in TED 4Q 2023
- Initiate POC studies in ANCA and AMR 4Q 2023

Additional pipeline


- ARGX-117: ARDA MMN interim results Mid-2023
- ARGX-117: Initiate DGF POC study 2H 2023
- ARGX-119: Initiate Phase 1 study 1Q 2023

* Pending decision from local regulatory authorities

Our mission continues...





Breadth and Depth Within Autoimmune Pipeline



Key: ■ NEUROLOGY ■ HEMATOLOGY AND RHEUMATOLOGY ■ DERMATOLOGY ■ NEPHROLOGY



Chronic Inflammatory Demyelinating Polyneuropathy ADHERE Trial



Efficacy analysis based on relapse (adjusted INCAT)

Study endpoint with 88 relapse events in stage B

Followed by Open Label Extension study